The Valley Desk

NCT03710564 · Interventional trial

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

Overall registry status Terminated

Phase 3

Conditions Age-Related Macular Degeneration

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov